Anakinra 100Mg/0.67Ml Inj Syringe (Period 1) + Placebo injection (Period 1) + Anakinra 100Mg/0.67Ml Inj Syringe (Period 2) + Placebo injection (Period 2)
Phase 2Recruiting 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Autoimmune Inner Ear Disease
Conditions
Autoimmune Inner Ear Disease, Meniere's Disease
Trial Timeline
Jan 3, 2019 → Dec 31, 2025
NCT ID
NCT03587701About Anakinra 100Mg/0.67Ml Inj Syringe (Period 1) + Placebo injection (Period 1) + Anakinra 100Mg/0.67Ml Inj Syringe (Period 2) + Placebo injection (Period 2)
Anakinra 100Mg/0.67Ml Inj Syringe (Period 1) + Placebo injection (Period 1) + Anakinra 100Mg/0.67Ml Inj Syringe (Period 2) + Placebo injection (Period 2) is a phase 2 stage product being developed by Swedish Orphan Biovitrum for Autoimmune Inner Ear Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT03587701. Target conditions include Autoimmune Inner Ear Disease, Meniere's Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03587701 | Phase 2 | Recruiting |
Competing Products
20 competing products in Autoimmune Inner Ear Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Satralizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| SHR0302 quick release tablets + SHR0302 sustained-release tablets | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| HR19042 Capsule, Tarpeyo®, Budenofalk® | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| HR19042 Capsules | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Enteric-coated Mycophenolate Sodium | Novartis | Phase 3 | 77 |
| Ianalumab + Placebo | Novartis | Phase 3 | 77 |
| VAY736 | Novartis | Phase 2/3 | 65 |
| remibrutinib | Novartis | Phase 1 | 33 |
| RO7049665 | Roche | Phase 2 | 52 |
| rituximab (Mabthera®) + Placebo | Roche | Phase 3 | 77 |
| NovoMix 30 + Tablet treatment | Novo Nordisk | Pre-clinical | 22 |
| branebrutinib + abatacept + branebrutinib placebo | Bristol Myers Squibb | Phase 2 | 51 |
| BMS-986165 | Bristol Myers Squibb | Phase 1 | 32 |
| Nivolumab | Bristol Myers Squibb | Phase 1 | 32 |
| Fludarabine + Cyclophosphamide + Tocilizumab | Bristol Myers Squibb | Phase 1 | 32 |
| BMS-986165 + Rosuvastatin | Bristol Myers Squibb | Phase 1 | 32 |
| SAR445088 | Sanofi | Phase 1 | 32 |
| BIVV020 | Sanofi | Phase 1 | 32 |
| rilzabrutinib | Sanofi | Phase 2 | 51 |
| rilzabrutinib + placebo | Sanofi | Phase 3 | 76 |